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Abstract: H ie present study reports on the treatment o f bleeding episodes 
and the natural history o f factor VIII inhibitors in 4 patients with acquired 
haemophilia A  postpartum. Low titre type II factor VIII inhibitors in 3 
patients and high titre type I inhibitor in 1 patient became apparent 
immediately to 7 months after delivery. High dose human factor VIII 
concentrate substitution was effective in controlling bleeding episodes in two 
cases of factor VIII inhibitor type II, but ineffective in 1 patient with high 
titre type I factor VIII inhibitor. High dose gammaglobulin intravenously in
1 patient with type II factor VIII inhibitor induced a partial correction of 
factor VIIIc levels for 2 wk. Immunosuppressive treatment in all 4 patients 
with acquired haemophilia A  postpartum did not reduce the potency of the 
factor VIII inhibitors. The low titre type II inhibitors spontaneously 
disappeared in all 3 patients within a few months to 1 yr after discontinuation 
of the immunosuppressive treatment. The high titre type I factor VIII 
inhibitor persisted for more than 24 yr. We conclude that 
immunosuppression in 4 wom en with acquired haemophilia A  postpartum  
did not significantly affect the factor VIII inhibitor titre.
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Introduction
The clinical suspicion of acquired haemophilia A 
usually arises in elderly patients, who develop 
spontaneous soft tissue bleeding and bruising, 
haemarthros and/or gastrointestinal bleeding (1). 
Laboratory investigations characteristically show a 
prolonged APTT and a reduced factor VIII level 
due io an inhibitory antibody against factor VIII 
coagulant activity (VIIIc). Acquired haemophilia 
A due to an inhibitor against factor VIIIc in healthy 
young woman postpartum is rare (2,3). The present 
study reports on the efficacy of high dose factor VIII 
on bleeding symptoms and the inefficacy of immu­
nosuppression on the factor VIII inhibitor titre in 4 
cases of acquired haemophilia A postpartum. Our 
results are discussed in view of the literature on 
acquired haemopilia A postpartum (1-9).
Methods
Coagulation tests were performed using routine 
procedures. Factor VIII coagulant activity (VIIIc) 
was assayed by means of the Automatic Coagula­
tion Laboratory (ACL; Instrumental Laboratory, 
IJsselstein, The Netherlands) using factor VIIIc 
deficient plasma (Ortho Diagnostic Systems, 
Beerse, Belgium),
The potency of inhibitor activity against factor 
VIIIc was assayed in mixtures of the patient’s 
plasma undiluted or diluted with Michaelis buffer 
(pH 7.42) and pooled normal plasma or porcine 
factor VIII (Hyate : C, Speywood Pharmaceuticals, 
Berkshire, England) and expressed in Bethesda 
Units (BU) (4). The inhibitors were classified as 
type I or type II following the criteria of Biggs 
et al. (5, 6) and Gawryl & Hoyer (7).
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Table 1. Laboratory characteristics and final outcome in 4 cases of acquired haemophilia postpartum
Case 1
Case 2
Case 3
Case 4
Number of preg- Time since last 
Age of patient nancies prior to delivery at onset 
years symptoms of bleeding
37
22
31
24
1 4 months
7 months
2 month
0
F. VI lie 
U/ml
0,02
0.01-0.02
<0.01
<0.01
Inhibitor titre 
Bethesda units
7.9
12
24
295-625
Outcome
Spontaneous
remission?
Spontaneous
remission
Spontaneous
remission
No
remission
Time lapse 
between onset 
bleeding and 
outcome
28 months
>24 years
Subsequent
pregnancies
2 months No
Yes, in remission, 
10 months no recurrence
No
No
Results
Laboratory findings
The laboratory characteristics and final outcome in 
4 cases of acquired haemophilia postpartum are 
summarized in Table 1. The inhibitors against 
factor VIII could be characterized as low titre type 
II in 3 cases and high titre type I in case 4. The 
type II inhibitor of case 3 did not cross-react with 
porcine factor VIII, Hyate-C. The type I inhibitor 
of case 4 cross-reacted with porcine factor VIII, 
Hyate : C (22 BU). The type II inhibitors of cases 
1 and 2 were not tested against porcine factor VIII.
Clinical observations
Case 1 presented in February 1990 with bruises 
and ecchymoses. Continuous factor VIII (Factor 
VIII CPS, Central Laboratory Bloodtransfusion, 
Amsterdam) infusion for the treatment of haemar- 
thros and bruises was clinically effective and treat» 
ment with prednisone 1 mg/kg was started (Fig. 1). 
The factor VIII inhibitor disappeared 2 months 
after diagnosis while still on prednisone treatment 
20 mg/d (Fig. 1) and did not recur during a follow- 
up period of 5 yr.
Case 2 presented in September 1990 with bleeding 
after tooth extraction and menorrhagia 7 months 
postpartum. Cyclophosphamide 100 mg/d (0.7 mg/ 
kg/d) for 1 month did not affect the factor VIII 
inhibitor titre and factor VIIIc levels. The inhibitor 
against factor VIII spontaneously disappeared 
several months after discontinuation of cyclophos­
phamide (Fig. 2). A fourth pregnancy in 1992 was 
uneventful with no recurrence of an inhibitor 
against factor VIII.
Cose 3 presented in June 1991 with muscle and soft 
tissue bleedings, menorrhagia, bruises and haemar- 
thros. A single dose of 4000 U human factor VIII 
(Hemophil-M Baxter, Hyland Division, Lessines,
Factor VIII Inhibitor postpartum 
B ethesda Units (BU)
8 4 2 BU
F VIII c
0.80-1 u/ml
0.50-
0 .10-
F vin
U/day
7000
5000
3000
75 mg/day
50 Prednisone
30
m m
10
days 30 60
ì= * V i
90 2 years
Fig, 1. Factor VIII substitution and prednisone treatment in 
relation to factor VIIIc and factor VIII inhibitor levels in 
patient 1 with acquired haemophilia A postpartum.
Belgium) corrected the prolonged APTT due to a 
rise of factor VIIIc from <0.01 U/ml to 0.36 U/ml 
(Fig, 3), which was followed by a curvilinear dis­
appearance of factor VIIIc from the circulation to 
0.10 U/ml at 6h postinfusion. Treatment of major 
bleeding from haemorrhoides with Hemophil-M 
was effective and resulted in normal factor VIIIc 
levels with the disappearance of the factor VIII 
inhibitor (Fig. 3). Concomitantly, treatment was 
started with prednisone 1 mg/kg/d for 6 wk followed 
by cyclophosphamide 2 mg/kg/d from the 3rd to 6th 
week of prednisone treatment (Tie. 3). The inhibitor
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Factor VIÜ Inhibitor postpartum 
Bethesda Units (BU)
1' 7 12 10 12 7 3 5 1 BU 0 0 0 BU
F VIIIc U/ml
1.00-
Cyclophosphamide
APTT(seconds)
0.50
0
days months
Fig. 2. No effect of cyclophophamide treatment on the activated partial thromboplastin time (APTT), and factor VIIIc and factor 
VIII inhibitor levels in patient 2 with acquired haemophilia A postpartum.
against factor VIII reappeared after discontinuation 
of factor VIII substitution and immunosuppression. 
Subsequently, high dose gamma-globulin 0.5 g/kg/d 
for 5 d resulted in a transient decrease of the inhib­
itor titre and factor VIIIc levels of sufficient haemo­
static potency for 2-3 wk (Fig. 4).
Case 4 the second pregnancy of a 24-yr-old woman 
in January 1972 was complicated by hypovolaemic 
shock and the birth of a lifeless child by Caesarian 
section under the cover of 32 units of blood in 
the postpartum period. The excessive bleedings 
were due to acquired haemophilia A (Table 1).
prednisone 
cyclophosphamide
Bethesda Units (BU)
20 BU 26
I 4
Minor bleedings
F VU! c (•) ^ ^ +
3.00-
BU
Bleeding episode
2.00-
1.00-
0.60- _
0.30-
0.10-
F VIII Units 
4000-
2000-
10 20
1991
1 mg/kg/day
2 mg/kg/day
F VIII (v 4000 3x/day
0 hrs 24
40
i 
45
2000 3x/day
i
50
T
55 58
15
I
12 10 10 5 1 BU
I I ; I +
High dose 
Gammaglobuline
1992
--- 1— i"PM‘ i v i r r
1993
-----n— “ 1 '------1
60 80 100 120
Days
12 12 
months
Fig. 3. Effectiveness of factor VIII substitution and ineffectiveness of prednisone/cyclophophamide treatment in patient 3 with 
acquired haemophilia A postpartum.
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F Ville
u/ml
0.60 -,
0.50-
Bethesda Units {BU}
1 2  8  7 5 4
I  i  W  i
2 1 10BU
0.40-
0.30-
0.20-
0.10-
Intravenous 
Immunoglobulin 
0*5 gram/ g/Day
T---- 1
20 40 Days
Fig. 4. The effect of intravenous gammaglobulin on factor VIIIc and factor VIII inhibitor levels in patient 3 with acquired 
haemophilia A postpartum (see Fig. 3).
Prednisone 1 mg/kg for 3 wk and tapering off the 
dose within 5 months was ineffective. In 1977 the 
inhibitor potency was 600 BU. Factor VIII levels 
remained <1% even after transfusion of 10,000 U 
cryoprecipitate for the treatment of severe haem- 
arthros of the left knee. Recurrent joint bleedings 
led to severe arthropathy of the knee joints. The 
factor VIII inhibitor persisted (625 BU in 1984 and 
420 BU in 1988) and completely inhibited human 
factor VIIIc both in vivo and in vitro, which is 
consistent with a type I factor VIII inhibitor.
Discussion
Treatment of bleeding symptoms in acquired 
haemophilia A should be based upon the clinical 
circumstances and the inhibitor characteristics in 
the Bethesda assay (10, 11). Success with factor 
VIII concentrate depends on both the type and 
potency of the inhibitor. The potency of the factor 
VIII inhibitor in women postpartum is usually low 
A non-linear type II factor VIIIc inactivation is 
usually seen in women with acquired haemophilia 
postpartum (2). Type II antibodies do not com­
pletely inactivate factor VIIIc even when tested 
undiluted (5, 6). Therefore, it is not necessary 
to neutralize the inhibitor completely in order to 
obtain in vivo factor VIIIc levels of sufficient 
haemostatic potency (2, 7). High dose human fac­
tor VIII substitution in the emergency situation of 
major bleeding in case 3 with type II factor VIII 
inhibitor resulted in correction of factor VIII levels 
and disappearance of the inhibitor as long as the 
substitution therapy was continued.
DDAVP intravenously will be of no clinical use 
in controlling bleedings, because it induces no or 
slight increase of factor VIIIc, which is rapidly 
inactivated by the factor VIII inhibitor. In case 
3, high-dose immunoglobulin in standard dosages 
(0.5 g/kg for 5 d) was transiently effective and no 
cross reactivity of the inhibitor to porcine factor 
VIIIc was demonstrated retrospectively (10, 11). 
Therefore, high dose immunoglobulin intravenously 
as well as substitution with porcine factor VIII 
(Hyate : C) might have been a better alternative 
and even more effective than human factor VIII to 
arrest bleedings in this case.
The high titre type I factor VIII antibodies 
persisted for more than 24 yr in case 4 and cross­
reacted with porcine factor VIII, Hyate : C. Such 
high titre type I factor VIII inhibitors do not 
respond to human and porcine factor VIII sub­
stitutions and have a high risk of life-threatening 
bleeding complications, which should be treated 
preferentially with recombinant factor VII or alter­
natively with FEIBA (10,11).
Postpartum factor VIII inhibitors usually persist 
for a few months to several years (2). The final 
outcome of postpartum inhibitors is favorable with 
a probability of spontaneous disappearence of the 
inhibitor of almost 100% at 30 months (2, 3). A
second pregnancy in documented patients with 
prior postpartum factor VIII inhibitors did not 
cause a reappearance of the factor VIII inhibitor 
(2, 3, 8, 9) (case 2, Table 1).
The effect of immunosuppressive treatment on 
the natural history of factor VIII inhibitors in 
women postpartum is questionable. In a retro-
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spective analysis of 51 postpartum factor VIII 
inhibitor patients, steroid treatment is not superior 
to no treatment and immunosuppression did not 
induce a complete remission, but may have slightly 
reduced the time to complete remission. The time 
to the disappearence of the factor VIII inhibitor was 
8 months in 18 patients with immunosuppressive 
treatment, 12 months in 23 patients with steroid 
treatment and 16 months in 10 patients without 
steroids or immunosuppressive treatment (3).
The present study extends our original observa­
tions in 1978 (2) and the findings derived from the 
literature (2, 3), that there is no evidence for the 
benefit of immunosuppressive treatment in young 
women with acquired haemophilia A postpartum. 
In contrast, immunosuppression is a first-choice 
treatment in acquired haemophilia A affecting 
elderly patients, because it induces a transient or 
persistent disappearance of the inhibitory auto- 
antibodies against factor VIII in the majority of 
these cases (12).
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